在堪萨斯州医疗补助计划的入学者中使用瓦雷尼克林
Nathalia M Machado1, Aaron J Katz2, Kimber P Richter2
1TSET Health Promotion Research Center, Stephenson Cancer Center, The University of Oklahoma Health Campus, Oklahoma City, Oklahoma, United States of America.
PloS one
|October 7, 2025
概括
关键的戒烟药物瓦伦尼克林在堪萨斯州的医疗补助计划中被滥用,只有12.7%的人接受了它,1.6%的人完成了治疗. 在这个人群中,瓦雷尼克林的使用存在显著的人口差异.
科学领域:
- 公共卫生 公共卫生
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在医疗补助受益者中,吸烟仍然非常普遍,超过私人保险人群的吸烟率.
- 在这一群体中,有效的戒烟疗法,如瓦里尼克林,未得到充分利用.
- 了解药物使用模式对于改善医疗补助计划注册者戒烟干预措施至关重要.
研究的目的:
- 分析2014年至2021年间堪萨斯州医疗补助 (KanCare) 招生人群中瓦雷尼克林使用趋势.
- 评估FDA在2016年删除黑子警告对瓦雷尼克林使用的影响.
- 为了识别瓦雷尼克林处方和治疗完成率的人口差异.
主要方法:
- 一项回顾性队列研究,利用2014年1月1日至2021年12月31日的KanCare药房索赔数据.
- 包括78,295名新的成人入学 (18+) 连续覆盖至少11个月.
- 主要结局:瓦雷尼克林处方说法;次要结局:第一次处方的时间,12周治疗完成和人口统计学关联.
主要成果:
- 只有12.7%的KanCare吸烟者接受了瓦里尼克林,只有1.6%完成了整个12周的治疗过程.
- 瓦伦尼克林被处方给研究队列的3.8%,从招生到第一次处方的平均时间为1.5年.
- 使用率在男性 (4.8%) 与女性 (3.4%) 之间更高,并且因种族/种族而异 (白人:4.4%,黑人:2.7%,美洲印第安人:2.5%,西班牙裔:1.6%).
结论:
- 在堪萨斯州的医疗补助受益者中,尽管吸烟率很高,但瓦伦尼克林的使用量显著不足.
- 在瓦雷尼克林使用方面观察到显著的人口差异,男性和非西班牙裔白人更有可能接受这种药物.
- 医疗补助计划需要加强努力,以确保公平获得有效的戒烟治疗,如瓦里尼克林.
相关概念视频
Inhaled Medications
746
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
746
Dosage Regimens: Partial Pharmacokinetic Parameters
150
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
150
Drug Dosage Regimen: Overview
4.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.4K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
671
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
671
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
808
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
808
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
583
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
583


